Menu Search
Equities

Sprint Bioscience AB

5JA1:FRA

Sprint Bioscience AB

Actions
  • Price (EUR)0.083
  • Today's Change-0.003 / -3.49%
  • Shares traded1.00k
  • 1 Year change-47.13%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Sprint Bioscience AB grew revenues 60,725.30% from 83.00k to 50.49m while net income improved from a loss of 60.17m to a smaller loss of 438.00k.
Gross margin76.51%
Net profit margin17.31%
Operating margin16.38%
Return on assets41.28%
Return on equity128.58%
Return on investment128.58%
More ▼

Cash flow in SEKView more

In 2023, Sprint Bioscience AB increased its cash reserves by 69.31%, or 20.44m. The company earned 22.87m from its operations for a Cash Flow Margin of 45.30%. In addition the company generated 24.00k cash from financing while 2.45m was spent on investing.
Cash flow per share0.2217
Price/Cash flow per share5.28
Book value per share0.2677
Tangible book value per share0.2677
More ▼

Balance sheet in SEKView more

Sprint Bioscience AB has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 49.93m.
Current ratio1.47
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.